Naval Daver

3.5k total citations · 1 hit paper
144 papers, 1.5k citations indexed

About

Naval Daver is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Naval Daver has authored 144 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Hematology, 57 papers in Genetics and 40 papers in Molecular Biology. Recurrent topics in Naval Daver's work include Acute Myeloid Leukemia Research (96 papers), Chronic Myeloid Leukemia Treatments (44 papers) and Acute Lymphoblastic Leukemia research (34 papers). Naval Daver is often cited by papers focused on Acute Myeloid Leukemia Research (96 papers), Chronic Myeloid Leukemia Treatments (44 papers) and Acute Lymphoblastic Leukemia research (34 papers). Naval Daver collaborates with scholars based in United States, Japan and Germany. Naval Daver's co-authors include Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Nicholas J. Short, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Gautam Borthakur, Jörge E. Cortes and Elias Jabbour and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Naval Daver

126 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

2020 243 citations Nicholas J. Short, Marina Konopleva et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Naval Daver United States	16	1.2k	607	546	372	348	144	1.5k
Musa Yılmaz United States	25	1.5k 1.3×	689 1.1×	641 1.2×	596 1.6×	553 1.6×	149	2.0k
Ulrike Schäkel Germany	12	1.7k 1.4×	852 1.4×	450 0.8×	617 1.7×	364 1.0×	15	2.0k
C. Michel Zwaan Netherlands	17	689 0.6×	349 0.6×	323 0.6×	186 0.5×	167 0.5×	36	992
Elias Jabbour United States	17	955 0.8×	306 0.5×	283 0.5×	561 1.5×	255 0.7×	67	1.3k
Anders Castor Sweden	18	755 0.6×	455 0.7×	806 1.5×	133 0.4×	309 0.9×	46	1.5k
S. Faderl United States	16	882 0.7×	417 0.7×	214 0.4×	393 1.1×	240 0.7×	24	1.2k
Tanja A. Grüber United States	18	552 0.5×	306 0.5×	555 1.0×	130 0.3×	260 0.7×	51	1.1k
Thibaut Leguay France	21	1.2k 1.0×	262 0.4×	1.3k 2.3×	353 0.9×	461 1.3×	61	1.9k
Prashant Tembhare India	17	438 0.4×	233 0.4×	296 0.5×	261 0.7×	300 0.9×	97	909
Claire Schwab United Kingdom	22	1.2k 1.0×	378 0.6×	1.5k 2.7×	157 0.4×	217 0.6×	46	1.8k

Countries citing papers authored by Naval Daver

Since Specialization

Citations

This map shows the geographic impact of Naval Daver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naval Daver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naval Daver more than expected).

Fields of papers citing papers by Naval Daver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naval Daver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naval Daver. The network helps show where Naval Daver may publish in the future.

Co-authorship network of co-authors of Naval Daver

This figure shows the co-authorship network connecting the top 25 collaborators of Naval Daver. A scholar is included among the top collaborators of Naval Daver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naval Daver. Naval Daver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kantarjian, Hagop M., Nitin Jain, Jayastu Senapati, et al.. (2025). Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia. Blood. 146(Supplement 1). 5131–5131.

Short, Nicholas J., Sanam Loghavi, Musa Yılmaz, et al.. (2025). Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor. Haematologica.

Jain, Nitin, Tapan M. Kadia, Courtney D. DiNardo, et al.. (2025). Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study. Blood. 146(Supplement 1). 1571–1571.

Senapati, Jayastu, H. Kantarjian, Edward Ayoub, et al.. (2024). Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up. Blood. 144(Supplement 1). 1513–1513. 1 indexed citations

McCall, David, Ramya Ramakrishnan, César Núnêz, et al.. (2024). Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience. Cancers. 16(22). 3886–3886. 1 indexed citations

Bataller, Álex, Hagop M. Kantarjian, Alexandre Bazinet, et al.. (2024). Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Blood. 144(Supplement 1). 56–56. 3 indexed citations

Pasvolsky, Oren, Rima M. Saliba, Sairah Ahmed, et al.. (2024). Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 24(11). e819–e826. 2 indexed citations

Takahashi, Koichi, Sanam Loghavi, Tapan M. Kadia, et al.. (2024). FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.. Journal of Clinical Oncology. 42(16_suppl). 6519–6519. 8 indexed citations

Daver, Naval, Pau Montesinos, Jessica K. Altman, et al.. (2024). A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.. Journal of Clinical Oncology. 42(16_suppl). TPS6585–TPS6585. 1 indexed citations

10.

Arora, Sankalp, Jayastu Senapati, Lucia Masárová, et al.. (2024). Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).. Journal of Clinical Oncology. 42(16_suppl). 6572–6572. 1 indexed citations

11.

Senapati, Jayastu, Elias Jabbour, Nicholas J. Short, et al.. (2024). Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 1442–1442. 3 indexed citations

12.

Maiti, Abhishek, Pierre Péterlin, Daniel Morillo, et al.. (2024). ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction. Blood. 144(Supplement 1). 2876–2876. 1 indexed citations

13.

Wang, Bofei, Tianhao Li, Naval Daver, et al.. (2024). Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia. Journal for ImmunoTherapy of Cancer. 12(2). e008318–e008318. 5 indexed citations

14.

DiNardo, Courtney D., Kelly S. Chien, Danielle Hammond, et al.. (2024). Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia. Blood. 144(Supplement 1). 1511–1511. 1 indexed citations

15.

Sasaki, Koji, Courtney D. DiNardo, Nicholas J. Short, et al.. (2023). Protective Role of Oxaliplatin Among Platinum-Based Therapies in the Development of Therapy-Related Myeloid Neoplasms. Blood. 142(Supplement 1). 4220–4220.

16.

Short, Nicholas J., Elias Jabbour, Nitin Jain, et al.. (2023). S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY. HemaSphere. 7(S3). e4968152–e4968152. 2 indexed citations

17.

Fiskus, Warren, Christopher P. Mill, Christine Birdwell, et al.. (2023). Abstract 1140: Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML. Cancer Research. 83(7_Supplement). 1140–1140.

18.

Daver, Naval, Anthony S. Stein, Dale L. Bixby, et al.. (2023). Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). Blood. 142(Supplement 1). 4278–4278. 4 indexed citations

19.

Bataller, Álex, Alexandre Bazinet, Gautam Borthakur, et al.. (2023). Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial. Blood. 142(Supplement 1). 4256–4256. 9 indexed citations

20.

Jabbour, Elias, Nicholas J. Short, Farhad Ravandi, et al.. (2018). Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. The Lancet Haematology. 5(12). e618–e627. 160 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact